Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples